o-Vanillin

o-Vanillin is an isomer of vanillin, the compound that gives vanilla its smell, and almost everything known about it as a senolytic comes from one research programme at McGill University focused on a specific problem: the degenerating intervertebral disc.

The rationale is unusually concrete. Discs accumulate senescent cells, those cells secrete inflammatory and matrix-degrading factors, and chronic low back pain is one of the most common and least well treated conditions in medicine. If senescent cells drive part of that, clearing them locally is a more tractable proposition than clearing them from a whole body.

The 2019 work compared curcumin and o-vanillin in cells isolated from human discs, taken from organ donors and from patients having surgery for low back pain. Degenerate discs carried about 40 percent more senescent cells than non-degenerate discs from unrelated individuals, and about 10 percent more when the comparison was within the same person. Both compounds cleared senescent cells, reduced SASP factor expression, and increased matrix synthesis, acting through Nrf2 and NF-kB.

A 2020 eLife paper went further, comparing o-vanillin with RG-7112, a synthetic MDM2 inhibitor, and taking the work into intact degenerating human discs kept alive ex vivo. A single dose improved disc matrix homeostasis, and the improvement tracked with fewer senescent cells and less SASP. A 2021 paper showed that activating Toll-like receptor 2 and 6 induced senescence in human disc cells and that o-vanillin reduced senescence, SASP and TLR-2 expression.

The first in vivo test came in 2025. Sparc-null mice, a model that develops low back pain, were given o-vanillin and RG-7112 orally, alone and in combination. Treatment reduced pain behaviour, removed senescent cells from the disc and spinal cord, reduced SASP release, lowered disc degeneration scores, improved vertebral bone quality and reduced pain-marker expression in the spinal cord.

That is a coherent programme with a clear target, run by one group, entirely in cells, human tissue and mice. There is no human trial.

There is no human evidence. No trial of o-vanillin has been registered or published, so nothing here describes what it does in a living person.

Two things make this page worth reading anyway. The first is that the human tissue work is better than most preclinical senolytic evidence. Cells came from identified human donors and from patients undergoing surgery for back pain, the senescent burden was quantified within the same individual as well as between individuals, and the 2020 work used intact human discs kept alive rather than isolated cells. That is a great deal closer to a person than a cancer cell line. It is still not a person.

The second is the economics. o-Vanillin is a simple, cheap, unpatentable molecule. Nobody can own it, so nobody has an incentive to fund the trial that would settle what it does, and its thin clinical record is at least partly an economic fact rather than a verdict on the compound. The same programme's synthetic comparator, RG-7112, has been through human safety testing in oncology, which is the sort of asymmetry that shapes which senolytics get tested in people.

No senolytic of any kind has yet improved a clinical outcome in a randomised human trial. That sentence is the single most useful thing to carry into any senolytic discussion. Senescent cell burden has been reduced in people, by dasatinib plus quercetin, and the field has measured that reduction in skin and fat biopsies. What has not followed is a randomised trial in which people who got a senolytic ended up walking further, breaking fewer bones, or living longer than people who did not. The two randomised trials that tried, in pulmonary fibrosis and in postmenopausal bone turnover, did not separate from control.